Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

2.900 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
The 3 Best Gene Editing Stocks on the Frontier of Medicine
Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December. 
Via InvestorPlace
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio? 
Via The Motley Fool
3 Long-Term Growth Stocks Analysts Are Bullish On
Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two. 
Via InvestorPlace
3 Biotech Stocks That Are Betting on the Future of Gene Editing
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
Via InvestorPlace
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. 
Via Benzinga
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
A Preview Of Editas Medicine's Earnings
Via Benzinga
Analyst Ratings for Editas Medicine
Via Benzinga
Is Editas Stock a Buy Now?
Shares of the gene-editing company are close to their 52-week lows. Does it make sense to buy the stock now? 
Via The Motley Fool
Expert Ratings for Editas Medicine
Via Benzinga
Earnings Scheduled For November 3, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million. 
Via Benzinga
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
3 Gene Editing Stocks to Generate Super-Charged Gains
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
Both are in a race against time to commercialize a medicine before cash runs out. 
Via The Motley Fool
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! 
Via InvestorPlace
NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things
It's key to understand the resources it will take to deliver a company's pipeline. 
Via The Motley Fool
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
The better of the pair should be able to beat Bluebird Bio. 
Via The Motley Fool
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
Via Benzinga
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors. 
Via Benzinga
Why Editas Medicine Stock Is Soaring Today
Investors are cheering a big analyst upgrade for the gene-editing stock. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.